Skip to main content

Advertisement

SpringerLink
Log in

Residual kidney function modifies the effect of cinacalcet on serum phosphorus levels among peritoneal dialysis patients

  • Research Letter
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

Data are not available to the public due to the policy of the Japanese Society for Dialysis Therapy.

References

  1. Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM et al (2006) Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium X phosphate. Clin J Am Soc Nephrol 1:305–312

    Article  PubMed  CAS  Google Scholar 

  2. Chonchol M, Locatelli F, Abbound HE, Charytan C, de Francisco AL, Jolly S et al (2009) A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53:197–207

    Article  PubMed  CAS  Google Scholar 

  3. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M (2012) Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 27:784–790

    Article  PubMed  CAS  Google Scholar 

  4. Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T et al (2015) An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial 19:540–574

    Article  PubMed  CAS  Google Scholar 

  5. Revic D, Matovinovic MS, Rasic S, Kes P, Hamzic-Mehmedbasic A (2015) The effect of preserved residual renal function on left ventricular structure in non-anuric peritoneal dialysis patients. Kidney Blood Press Res 40:500–508

    Article  Google Scholar 

  6. Wu M, Wu H, Huang X, Ye H, Huang F, Yu X et al (2019) Associations between serum mineral metabolism parameters and mortality in patients on peritoneal dialysis. Nephrology 24:1148–1156

    Article  PubMed  CAS  Google Scholar 

  7. Liu CT, Lin YC, Lin YC, Kao CC, Chen HH, Hsu CC et al (2017) Roles of serum calcium, phosphorus, PTH and ALP on mortality in peritoneal dialysis patients: a nationwide, population-based longitudinal study using TWRDS 2005–2012. Sci Rep 7:33. https://doi.org/10.1038/s41598-017-00080-4

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Lopes MB, Karaboyas A, Zhao J, Johnson DW, Kanjanabuch T, Wilkie M et al (2023) Association of single and serial measures of serum phosphorus with adverse outcomes in patients on peritoneal dialysis: results from the international PDOPPS. Nephrol Dial Transplant 38:193–202

    Article  PubMed  CAS  Google Scholar 

  9. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K et al (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327–1339

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We appreciate the Committee of Renal Data Registry of JSDT for providing us with the data, and the members of the Japanese Society for Dialysis Therapy for contributing to JRDR. The opinions reflected in this manuscript are those of the authors alone and do not reflect an official position of JSDT.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Nephrology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 4678601, Japan

    Miho Murashima & Takayuki Hamano

  2. Department of Nephrology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan

    Naohiko Fujii

  3. Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

    Shunsuke Goto

  4. Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy, Tokyo, Japan

    Shunsuke Goto, Takeshi Hasegawa, Masanori Abe & Norio Hanafusa

  5. Showa University Research Administration Center (SURAC), Showa University, Tokyo, Japan

    Takeshi Hasegawa

  6. Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan

    Masanori Abe

  7. Department of Blood Purification, Tokyo Women’s Medical University, Tokyo, Japan

    Norio Hanafusa

  8. Division of Nephrology, Endocrinology, and Metabolism, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    Masafumi Fukagawa

  9. Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

    Takayuki Hamano

  10. Division of Nephrology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan

    Takeshi Hasegawa

  11. Department of Hygiene, Public Health and Preventive Medicine, Graduate School of Medicine, Showa University, Tokyo, Japan

    Takeshi Hasegawa

Authors
  1. Miho Murashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naohiko Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shunsuke Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masanori Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Norio Hanafusa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masafumi Fukagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takayuki Hamano
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MM: conception and design of the study, data analysis, interpretation of the data, and drafting of the manuscript. NF: review and approval of the final manuscript. SG: review and approval of the final manuscript. THas: conception and design of the study, interpretation of the data, and review and approval of the final manuscript. MA: review and approval of the final manuscript. NH: review and approval of the final manuscript. MF: review and approval of the final manuscript. THam: conception and design of the study, interpretation of the data, and review and approval of the final manuscript.

Corresponding author

Correspondence to Miho Murashima.

Ethics declarations

Conflict of interest

MM receives honoraria from Kyowa Kirin Co., Ltd., and Torii Pharmaceutical Co., Ltd. NF receives honoraria from Astellas Pharm Inc., Bayer Yakuhin Ltd., Kissei Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., and Torii Pharmaceutical Co., Ltd. SG receives research funds from Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd., and Chugai Pharmaceutical Co., Ltd. and honoraria from Kyowa Kirin Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Astellas Pharm Inc. THas receives honoraria from Kyowa Kirin Co., Ltd., Baxter, and Termo. MF receives research funds from Kyowa Kirin Co., Ltd., and honoraria from Kyowa Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., Bayer Ykuhin, Ltd., Ono Pharmaceutical Co., Ltd., and Sanwa Kagaku Kenkyusho Co., Ltd. MA receives research funds from Torii Pharmaceutical Co., Ltd., and Kyowa Kirin Co., Ltd., and honoraria from Kyowa Kirin Co., Ltd., Torii Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Bayer Yakuhin Ltd. THam receives research funds from Chugai Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Astellas Pharm Inc., and honoraria from Astellas Pharm Inc., Kissei Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Torii Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho. Co., Ltd., Ono Pharmaceutical Co., Ltd., and Bayer Yakuhin Ltd.

Ethical approval and Informed consent

The study protocol and waiver of consent were approved by the Medicine Ethics Committee of JSDT (Approval No.62). The study was conducted in accordance with the Declaration of Helsinki.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 28 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murashima, M., Fujii, N., Goto, S. et al. Residual kidney function modifies the effect of cinacalcet on serum phosphorus levels among peritoneal dialysis patients. J Nephrol (2024). https://doi.org/10.1007/s40620-023-01863-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40620-023-01863-x

Keywords

Search

Navigation